143 related articles for article (PubMed ID: 9341939)
1. bcl-2 protein expression in astrocytomas in relation to patient survival and p53 gene status.
Newcomb EW; Bhalla SK; Parrish CL; Hayes RL; Cohen H; Miller DC
Acta Neuropathol; 1997 Oct; 94(4):369-75. PubMed ID: 9341939
[TBL] [Abstract][Full Text] [Related]
2. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
[TBL] [Abstract][Full Text] [Related]
4. EGF-R and PDGF-R, but not bcl-2, overexpression predict overall survival in patients with low-grade astrocytomas.
Varela M; Ranuncolo SM; Morand A; Lastiri J; De Kier Joffé EB; Puricelli LI; Pallotta MG
J Surg Oncol; 2004 Apr; 86(1):34-40. PubMed ID: 15048678
[TBL] [Abstract][Full Text] [Related]
5. Expression of Bcl-2, Bcl-x, and Bax proteins in astrocytomas in relation to patient survival.
Daido S; Tamiya T; Ono Y; Terada K; Mizumatsu S; Ohmoto T
Brain Tumor Pathol; 2001; 18(2):123-9. PubMed ID: 11908868
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous alterations of retinoblastoma and p53 protein expression in astrocytic tumors.
Rathore A; Kamarajan P; Mathur M; Sinha S; Sarkar C
Pathol Oncol Res; 1999; 5(1):21-7. PubMed ID: 10079373
[TBL] [Abstract][Full Text] [Related]
7. Expression of retinoblastoma gene product and p21 (WAF1/Cip 1) protein in gliomas: correlations with proliferation markers, p53 expression and survival.
Korkolopoulou P; Kouzelis K; Christodoulou P; Papanikolaou A; Thomas-Tsagli E
Acta Neuropathol; 1998 Jun; 95(6):617-24. PubMed ID: 9650754
[TBL] [Abstract][Full Text] [Related]
8. TP53 gene mutations, nuclear p53 accumulation, expression of Waf/p21, Bcl-2, and CD95 (APO-1/Fas) proteins are not prognostic factors in de novo glioblastoma multiforme.
Kraus JA; Wenghoefer M; Glesmann N; Mohr S; Beck M; Schmidt MC; Schröder R; Berweiler U; Roggendorf W; Diete S; Dietzmann K; Heuser K; Müller B; Fimmers R; von Deimling A; Schlegel U
J Neurooncol; 2001 May; 52(3):263-72. PubMed ID: 11519857
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of wild-type p53 in astrocytomas is associated with increased p21 expression.
Ono Y; Tamiya T; Ichikawa T; Matsumoto K; Furuta T; Ohmoto T; Akiyama K; Seki S; Ueki K; Louis DN
Acta Neuropathol; 1997 Jul; 94(1):21-7. PubMed ID: 9224526
[TBL] [Abstract][Full Text] [Related]
10. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas.
Lang FF; Miller DC; Pisharody S; Koslow M; Newcomb EW
Oncogene; 1994 Mar; 9(3):949-54. PubMed ID: 8108140
[TBL] [Abstract][Full Text] [Related]
11. Manganese superoxide dismutase (MnSOD) is a malignant astrocytoma specific biomarker and associated with adverse prognosis in p53 expressing glioblastoma.
Shwetha SD; Shastry AH; Arivazhagan A; Santosh V
Pathol Res Pract; 2016 Jan; 212(1):17-23. PubMed ID: 26616112
[TBL] [Abstract][Full Text] [Related]
12. [Relationship of bcl-2 gene expression with cell proliferation and apoptosis in human gliomas].
Yu S; Pu P; Jiang D; An T; Guan X; Yang L
Zhonghua Bing Li Xue Za Zhi; 2000 Feb; 29(1):12-5. PubMed ID: 11866884
[TBL] [Abstract][Full Text] [Related]
13. Genetic sub-types of human malignant astrocytoma correlate with survival.
Leenstra S; Oskam NT; Bijleveld EH; Bosch DA; Troost D; Hulsebos TJ
Int J Cancer; 1998 Apr; 79(2):159-65. PubMed ID: 9583731
[TBL] [Abstract][Full Text] [Related]
14. Expression of survivin in astrocytic tumors: correlation with malignant grade and prognosis.
Kajiwara Y; Yamasaki F; Hama S; Yahara K; Yoshioka H; Sugiyama K; Arita K; Kurisu K
Cancer; 2003 Feb; 97(4):1077-83. PubMed ID: 12569609
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 expression in higher-grade human glioma: a clinical and experimental study.
Fels C; Schäfer C; Hüppe B; Bahn H; Heidecke V; Kramm CM; Lautenschläger C; Rainov NG
J Neurooncol; 2000 Jul; 48(3):207-16. PubMed ID: 11100818
[TBL] [Abstract][Full Text] [Related]
16. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations.
Shono T; Tofilon PJ; Bruner JM; Owolabi O; Lang FF
Cancer Res; 2001 Jun; 61(11):4375-81. PubMed ID: 11389063
[TBL] [Abstract][Full Text] [Related]
17. Absence of p53 gene mutations in a tumor panel representative of pilocytic astrocytoma diversity using a p53 functional assay.
Ishii N; Sawamura Y; Tada M; Daub DM; Janzer RC; Meagher-Villemure M; de Tribolet N; Van Meir EG
Int J Cancer; 1998 Jun; 76(6):797-800. PubMed ID: 9626343
[TBL] [Abstract][Full Text] [Related]
18. p53 immunoreactivity in astrocytomas and its relationship to survival.
al-Sarraj S; Bridges LR
Br J Neurosurg; 1995 Apr; 9(2):143-9. PubMed ID: 7632359
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins.
Ellison DW; Steart PV; Gatter KC; Weller RO
Neuropathol Appl Neurobiol; 1995 Aug; 21(4):352-61. PubMed ID: 7494604
[TBL] [Abstract][Full Text] [Related]
20. Human gliomas with wild-type p53 express bcl-2.
Alderson LM; Castleberg RL; Harsh GR; Louis DN; Henson JW
Cancer Res; 1995 Mar; 55(5):999-1001. PubMed ID: 7867012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
